ID   USB1_HUMAN              Reviewed;         265 AA.
AC   Q9BQ65; B4DWE3; B4DZW5; Q96FZ9; Q9H8X8;
DT   06-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   28-JUN-2023, entry version 152.
DE   RecName: Full=U6 snRNA phosphodiesterase 1 {ECO:0000305};
DE            Short=hUsb1 {ECO:0000303|PubMed:22899009};
DE   AltName: Full=3'-5' RNA exonuclease USB1 {ECO:0000305|PubMed:23022480};
DE            EC=4.6.1.- {ECO:0000269|PubMed:23022480, ECO:0000269|PubMed:23190533, ECO:0000269|PubMed:28887445, ECO:0000269|PubMed:30215753};
DE   AltName: Full=Mutated in poikiloderma with neutropenia protein 1 {ECO:0000303|PubMed:23022480};
DE            Short=Mutated in PN protein 1 {ECO:0000303|PubMed:23022480};
DE            Short=hMpn1 {ECO:0000303|PubMed:23022480};
GN   Name=USB1 {ECO:0000255|HAMAP-Rule:MF_03040,
GN   ECO:0000312|HGNC:HGNC:25792};
GN   Synonyms=C16orf57, Mpn1 {ECO:0000303|PubMed:23022480};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Synovium, and Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney, Pancreas, Placenta, Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INVOLVEMENT IN PN.
RX   PubMed=20004881; DOI=10.1016/j.ajhg.2009.11.014;
RA   Volpi L., Roversi G., Colombo E.A., Leijsten N., Concolino D., Calabria A.,
RA   Mencarelli M.A., Fimiani M., Macciardi F., Pfundt R., Schoenmakers E.F.,
RA   Larizza L.;
RT   "Targeted next-generation sequencing appoints c16orf57 as clericuzio-type
RT   poikiloderma with neutropenia gene.";
RL   Am. J. Hum. Genet. 86:72-76(2010).
RN   [5]
RP   INVOLVEMENT IN PN.
RX   PubMed=20503306; DOI=10.1002/ajmg.a.33455;
RA   Tanaka A., Morice-Picard F., Lacombe D., Nagy N., Hide M., Taieb A.,
RA   McGrath J.;
RT   "Identification of a homozygous deletion mutation in C16orf57 in a family
RT   with Clericuzio-type poikiloderma with neutropenia.";
RL   Am. J. Med. Genet. A 152:1347-1348(2010).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, INTERACTION WITH PLRG1;
RP   CDC5L AND PRPF19, AND MUTAGENESIS OF HIS-120 AND HIS-208.
RX   PubMed=23022480; DOI=10.1016/j.celrep.2012.08.031;
RA   Shchepachev V., Wischnewski H., Missiaglia E., Soneson C., Azzalin C.M.;
RT   "Mpn1, mutated in poikiloderma with neutropenia protein 1, is a conserved
RT   3'-to-5' RNA exonuclease processing U6 small nuclear RNA.";
RL   Cell Rep. 2:855-865(2012).
RN   [7]
RP   SUBCELLULAR LOCATION, FUNCTION, MUTAGENESIS OF HIS-208, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=22899009; DOI=10.1101/gad.193169.112;
RA   Mroczek S., Krwawicz J., Kutner J., Lazniewski M., Kucinski I.,
RA   Ginalski K., Dziembowski A.;
RT   "C16orf57, a gene mutated in poikiloderma with neutropenia, encodes a
RT   putative phosphodiesterase responsible for the U6 snRNA 3' end
RT   modification.";
RL   Genes Dev. 26:1911-1925(2012).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-120 AND HIS-208.
RX   PubMed=26213367; DOI=10.1016/j.febslet.2015.06.046;
RA   Shchepachev V., Wischnewski H., Soneson C., Arnold A.W., Azzalin C.M.;
RT   "Human Mpn1 promotes post-transcriptional processing and stability of
RT   U6atac.";
RL   FEBS Lett. 589:2417-2423(2015).
RN   [9]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=31832688; DOI=10.1093/nar/gkz1177;
RA   Nomura Y., Montemayor E.J., Virta J.M., Hayes S.M., Butcher S.E.;
RT   "Structural basis for the evolution of cyclic phosphodiesterase activity in
RT   the U6 snRNA exoribonuclease Usb1.";
RL   Nucleic Acids Res. 48:1423-1434(2020).
RN   [10] {ECO:0007744|PDB:4H7W}
RP   X-RAY CRYSTALLOGRAPHY (1.1 ANGSTROMS) OF 73-265, CATALYTIC ACTIVITY,
RP   FUNCTION, ACTIVE SITE, MUTAGENESIS OF HIS-120 AND HIS-208, AND ACTIVITY
RP   REGULATION.
RX   PubMed=23190533; DOI=10.1182/blood-2012-10-461491;
RA   Hilcenko C., Simpson P.J., Finch A.J., Bowler F.R., Churcher M.J., Jin L.,
RA   Packman L.C., Shlien A., Campbell P., Kirwan M., Dokal I., Warren A.J.;
RT   "Aberrant 3' oligoadenylation of spliceosomal U6 small nuclear RNA in
RT   poikiloderma with neutropenia.";
RL   Blood 121:1028-1038(2013).
RN   [11] {ECO:0007744|PDB:5V1M}
RP   X-RAY CRYSTALLOGRAPHY (1.47 ANGSTROMS) OF 79-265 IN COMPLEX WITH UMP,
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, REGION, AND
RP   ACTIVITY REGULATION.
RX   PubMed=28887445; DOI=10.1038/s41467-017-00484-w;
RA   Didychuk A.L., Montemayor E.J., Carrocci T.J., DeLaitsch A.T.,
RA   Lucarelli S.E., Westler W.M., Brow D.A., Hoskins A.A., Butcher S.E.;
RT   "Usb1 controls U6 snRNP assembly through evolutionarily divergent cyclic
RT   phosphodiesterase activities.";
RL   Nat. Commun. 8:497-497(2017).
RN   [12] {ECO:0007744|PDB:6D2Z, ECO:0007744|PDB:6D30, ECO:0007744|PDB:6D31}
RP   X-RAY CRYSTALLOGRAPHY (1.17 ANGSTROMS) OF 79-265 OF MUTANT HIS-208 IN
RP   COMPLEX WITH AMP; 3'-TERMINAL PUPU RESIDUE AND 3'-TERMINAL PUPA RESIDUE,
RP   MUTAGENESIS OF HIS-120; SER-122; TYR-202; HIS-208 AND SER-210, FUNCTION,
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, REGION, AND ACTIVE SITE.
RX   PubMed=30215753; DOI=10.1093/nar/gky812;
RA   Nomura Y., Roston D., Montemayor E.J., Cui Q., Butcher S.E.;
RT   "Structural and mechanistic basis for preferential deadenylation of U6
RT   snRNA by Usb1.";
RL   Nucleic Acids Res. 46:11488-11501(2018).
CC   -!- FUNCTION: 3'-5' RNA exonuclease that trims the 3' end of oligo(U) and
CC       oligo(A) tracts of the pre-U6 small nuclear RNA (snRNA) molecule,
CC       leading to the formation of a mature U6 snRNA 3' end-terminated with a
CC       2',3'-cyclic phosphate (PubMed:23022480, PubMed:22899009,
CC       PubMed:26213367, PubMed:31832688, PubMed:23190533, PubMed:28887445,
CC       PubMed:30215753). Participates in the U6 snRNA 3' end processing that
CC       prevents U6 snRNA degradation (PubMed:23022480, PubMed:22899009,
CC       PubMed:26213367, PubMed:31832688, PubMed:23190533, PubMed:28887445,
CC       PubMed:30215753). In addition also removes uridines from the 3' end of
CC       U6atac snRNA and possibly the vault RNA VTRNA1-1 (PubMed:26213367).
CC       {ECO:0000269|PubMed:22899009, ECO:0000269|PubMed:23022480,
CC       ECO:0000269|PubMed:23190533, ECO:0000269|PubMed:26213367,
CC       ECO:0000269|PubMed:28887445, ECO:0000269|PubMed:30215753,
CC       ECO:0000269|PubMed:31832688}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3'-end uridylyl-uridine-RNA = a 3'-end 2',3'-cyclophospho-
CC         uridine-RNA + uridine; Xref=Rhea:RHEA:46052, Rhea:RHEA-COMP:17384,
CC         Rhea:RHEA-COMP:17385, ChEBI:CHEBI:16704, ChEBI:CHEBI:85643,
CC         ChEBI:CHEBI:85644; Evidence={ECO:0000269|PubMed:23022480,
CC         ECO:0000269|PubMed:23190533, ECO:0000269|PubMed:28887445,
CC         ECO:0000269|PubMed:31832688, ECO:0000305|PubMed:22899009};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46053;
CC         Evidence={ECO:0000305|PubMed:22899009, ECO:0000305|PubMed:23022480};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3'-end uridylyl-adenosine-RNA = a 3'-end 2',3'-cyclophospho-
CC         uridine-RNA + adenosine; Xref=Rhea:RHEA:67896, Rhea:RHEA-COMP:17385,
CC         Rhea:RHEA-COMP:17386, ChEBI:CHEBI:16335, ChEBI:CHEBI:85644,
CC         ChEBI:CHEBI:176518; Evidence={ECO:0000269|PubMed:23190533,
CC         ECO:0000269|PubMed:30215753};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67897;
CC         Evidence={ECO:0000269|PubMed:23190533};
CC   -!- ACTIVITY REGULATION: 3'-5' RNA exonuclease activity is inhibited by a
CC       3' phosphate terminated RNA. {ECO:0000269|PubMed:23190533,
CC       ECO:0000269|PubMed:28887445}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=7.58 uM for UAUUUdUUU {ECO:0000269|PubMed:30215753};
CC         KM=9.75 uM for UAUUUdUAU {ECO:0000269|PubMed:30215753};
CC         KM=3.12 uM for UAUUUdUAU {ECO:0000269|PubMed:30215753};
CC         KM=7.17 uM for UAUUUdUAA {ECO:0000269|PubMed:30215753};
CC       pH dependence:
CC         Optimum pH is 7.5. {ECO:0000269|PubMed:28887445,
CC         ECO:0000269|PubMed:30215753};
CC   -!- SUBUNIT: Interacts with PLRG1, CDC5L and PRPF19.
CC       {ECO:0000269|PubMed:23022480}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|HAMAP-Rule:MF_03040,
CC       ECO:0000269|PubMed:22899009, ECO:0000269|PubMed:23022480}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9BQ65-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BQ65-2; Sequence=VSP_042878;
CC       Name=3;
CC         IsoId=Q9BQ65-3; Sequence=VSP_042936;
CC   -!- DISEASE: Poikiloderma with neutropenia (PN) [MIM:604173]: A
CC       genodermatosis characterized by poikiloderma, pachyonychia and chronic
CC       neutropenia. The disorder starts as a papular erythematous rash on the
CC       limbs during the first year of life. It gradually spreads centripetally
CC       and, as the papular rash resolves, hypo- and hyperpigmentation result,
CC       with development of telangiectasias. Another skin manifestation is
CC       pachyonychia, but alopecia and leukoplakia are distinctively absent.
CC       Patients have recurrent pneumonias that usually result in reactive
CC       airway disease and/or chronic cough. One of the most important
CC       extracutaneous symptoms is an increased susceptibility to infections,
CC       mainly affecting the respiratory system, primarily due to a chronic
CC       neutropenia and to neutrophil functional defects. Bone marrow
CC       abnormalities account for neutropenia and may evolve into
CC       myelodysplasia associated with the risk of leukemic transformation.
CC       Poikiloderma with neutropenia shows phenotypic overlap with Rothmund-
CC       Thomson syndrome. {ECO:0000269|PubMed:20004881,
CC       ECO:0000269|PubMed:20503306}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the 2H phosphoesterase superfamily. USB1 family.
CC       {ECO:0000255|HAMAP-Rule:MF_03040}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK023216; BAB14469.1; -; mRNA.
DR   EMBL; AK301494; BAG63005.1; -; mRNA.
DR   EMBL; AK303121; BAG64227.1; -; mRNA.
DR   EMBL; AC010543; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC012182; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC004415; AAH04415.1; -; mRNA.
DR   EMBL; BC006291; AAH06291.1; -; mRNA.
DR   EMBL; BC007774; AAH07774.1; -; mRNA.
DR   EMBL; BC010099; AAH10099.1; -; mRNA.
DR   EMBL; BC021554; AAH21554.1; -; mRNA.
DR   CCDS; CCDS10791.1; -. [Q9BQ65-1]
DR   CCDS; CCDS55997.1; -. [Q9BQ65-3]
DR   CCDS; CCDS55998.1; -. [Q9BQ65-2]
DR   RefSeq; NP_001182231.1; NM_001195302.1. [Q9BQ65-2]
DR   RefSeq; NP_001191840.1; NM_001204911.1. [Q9BQ65-3]
DR   RefSeq; NP_001317497.1; NM_001330568.1.
DR   RefSeq; NP_078874.2; NM_024598.3. [Q9BQ65-1]
DR   PDB; 4H7W; X-ray; 1.10 A; A=73-265.
DR   PDB; 5V1M; X-ray; 1.47 A; A=79-265.
DR   PDB; 6D2Z; X-ray; 1.18 A; A=79-265.
DR   PDB; 6D30; X-ray; 1.17 A; A=79-265.
DR   PDB; 6D31; X-ray; 1.20 A; A=79-265.
DR   PDBsum; 4H7W; -.
DR   PDBsum; 5V1M; -.
DR   PDBsum; 6D2Z; -.
DR   PDBsum; 6D30; -.
DR   PDBsum; 6D31; -.
DR   AlphaFoldDB; Q9BQ65; -.
DR   SMR; Q9BQ65; -.
DR   BioGRID; 122778; 50.
DR   IntAct; Q9BQ65; 25.
DR   MINT; Q9BQ65; -.
DR   STRING; 9606.ENSP00000219281; -.
DR   iPTMnet; Q9BQ65; -.
DR   PhosphoSitePlus; Q9BQ65; -.
DR   BioMuta; USB1; -.
DR   DMDM; 74732815; -.
DR   EPD; Q9BQ65; -.
DR   jPOST; Q9BQ65; -.
DR   MassIVE; Q9BQ65; -.
DR   MaxQB; Q9BQ65; -.
DR   PaxDb; Q9BQ65; -.
DR   PeptideAtlas; Q9BQ65; -.
DR   ProteomicsDB; 78632; -. [Q9BQ65-1]
DR   ProteomicsDB; 78633; -. [Q9BQ65-2]
DR   ProteomicsDB; 78634; -. [Q9BQ65-3]
DR   Antibodypedia; 29032; 157 antibodies from 24 providers.
DR   DNASU; 79650; -.
DR   Ensembl; ENST00000219281.8; ENSP00000219281.3; ENSG00000103005.13. [Q9BQ65-1]
DR   Ensembl; ENST00000423271.8; ENSP00000409792.3; ENSG00000103005.13. [Q9BQ65-3]
DR   Ensembl; ENST00000539737.6; ENSP00000446143.2; ENSG00000103005.13. [Q9BQ65-2]
DR   GeneID; 79650; -.
DR   KEGG; hsa:79650; -.
DR   MANE-Select; ENST00000219281.8; ENSP00000219281.3; NM_024598.4; NP_078874.2.
DR   UCSC; uc002emz.4; human. [Q9BQ65-1]
DR   AGR; HGNC:25792; -.
DR   CTD; 79650; -.
DR   DisGeNET; 79650; -.
DR   GeneCards; USB1; -.
DR   GeneReviews; USB1; -.
DR   HGNC; HGNC:25792; USB1.
DR   HPA; ENSG00000103005; Low tissue specificity.
DR   MalaCards; USB1; -.
DR   MIM; 604173; phenotype.
DR   MIM; 613276; gene.
DR   neXtProt; NX_Q9BQ65; -.
DR   OpenTargets; ENSG00000103005; -.
DR   Orphanet; 1775; Dyskeratosis congenita.
DR   Orphanet; 221046; Poikiloderma with neutropenia.
DR   PharmGKB; PA143485394; -.
DR   VEuPathDB; HostDB:ENSG00000103005; -.
DR   eggNOG; KOG3102; Eukaryota.
DR   GeneTree; ENSGT00390000004596; -.
DR   InParanoid; Q9BQ65; -.
DR   OMA; CGNKDFT; -.
DR   OrthoDB; 462025at2759; -.
DR   PhylomeDB; Q9BQ65; -.
DR   TreeFam; TF324364; -.
DR   PathwayCommons; Q9BQ65; -.
DR   SignaLink; Q9BQ65; -.
DR   BioGRID-ORCS; 79650; 69 hits in 1163 CRISPR screens.
DR   ChiTaRS; USB1; human.
DR   GenomeRNAi; 79650; -.
DR   Pharos; Q9BQ65; Tbio.
DR   PRO; PR:Q9BQ65; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q9BQ65; protein.
DR   Bgee; ENSG00000103005; Expressed in granulocyte and 178 other tissues.
DR   ExpressionAtlas; Q9BQ65; baseline and differential.
DR   Genevisible; Q9BQ65; HS.
DR   GO; GO:0045171; C:intercellular bridge; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000175; F:3'-5'-RNA exonuclease activity; IDA:UniProtKB.
DR   GO; GO:0016829; F:lyase activity; IEA:UniProtKB-KW.
DR   GO; GO:1990838; F:poly(U)-specific exoribonuclease activity, producing 3' uridine cyclic phosphate ends; IDA:UniProtKB.
DR   GO; GO:0008380; P:RNA splicing; IMP:UniProtKB.
DR   GO; GO:0034472; P:snRNA 3'-end processing; IMP:UniProtKB.
DR   GO; GO:0034477; P:U6 snRNA 3'-end processing; IDA:UniProtKB.
DR   Gene3D; 3.90.1140.10; Cyclic phosphodiesterase; 1.
DR   HAMAP; MF_03040; USB1; 1.
DR   InterPro; IPR027521; Usb1.
DR   PANTHER; PTHR13522:SF3; U6 SNRNA PHOSPHODIESTERASE; 1.
DR   PANTHER; PTHR13522; UNCHARACTERIZED; 1.
DR   Pfam; PF09749; HVSL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Hydrolase; Lyase; Nuclease; Nucleus;
KW   Reference proteome.
FT   CHAIN           1..265
FT                   /note="U6 snRNA phosphodiesterase 1"
FT                   /id="PRO_0000274391"
FT   REGION          1..72
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..15
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        16..30
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        120
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03040,
FT                   ECO:0000269|PubMed:23190533, ECO:0000269|PubMed:30215753"
FT   ACT_SITE        208
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03040,
FT                   ECO:0000269|PubMed:23190533, ECO:0000269|PubMed:30215753"
FT   BINDING         120..122
FT                   /ligand="AMP"
FT                   /ligand_id="ChEBI:CHEBI:456215"
FT                   /evidence="ECO:0000269|PubMed:30215753,
FT                   ECO:0007744|PDB:6D31"
FT   BINDING         164
FT                   /ligand="UMP"
FT                   /ligand_id="ChEBI:CHEBI:57865"
FT                   /evidence="ECO:0000269|PubMed:28887445,
FT                   ECO:0007744|PDB:5V1M"
FT   BINDING         202
FT                   /ligand="AMP"
FT                   /ligand_id="ChEBI:CHEBI:456215"
FT                   /evidence="ECO:0000269|PubMed:30215753,
FT                   ECO:0007744|PDB:6D31"
FT   BINDING         202
FT                   /ligand="UMP"
FT                   /ligand_id="ChEBI:CHEBI:57865"
FT                   /evidence="ECO:0000269|PubMed:28887445,
FT                   ECO:0007744|PDB:5V1M"
FT   BINDING         204..210
FT                   /ligand="AMP"
FT                   /ligand_id="ChEBI:CHEBI:456215"
FT                   /evidence="ECO:0000269|PubMed:30215753,
FT                   ECO:0007744|PDB:6D31"
FT   BINDING         206..210
FT                   /ligand="UMP"
FT                   /ligand_id="ChEBI:CHEBI:57865"
FT                   /evidence="ECO:0000269|PubMed:28887445,
FT                   ECO:0007744|PDB:5V1M"
FT   VAR_SEQ         150..265
FT                   /note="RFFFTANQVKIYTNQEKTRTFIGLEVTSGHAQFLDLVSEVDRVMEEFNLTTF
FT                   YQDPSFHLSLAWCVGDARLQLEGQCLQELQAIVDGFEDAEVLLRVHTEQVRCKSGNKFF
FT                   SMPLK -> SPHPGPHCLIGTKDAPVTQEIPKDLGALRQEPGSQTR (in isoform
FT                   3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042936"
FT   VAR_SEQ         150..167
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042878"
FT   VARIANT         115
FT                   /note="R -> K (in dbSNP:rs35025252)"
FT                   /id="VAR_053822"
FT   VARIANT         250
FT                   /note="Q -> E (in dbSNP:rs16959641)"
FT                   /id="VAR_030277"
FT   MUTAGEN         120
FT                   /note="H->A: Abolishes exoribonuclease activity. Does not
FT                   restore U6 snRNA processing when expressed in deleted mpn1
FT                   yeast cells; when associated with A-208. Increases the
FT                   accumulation of unspliced pre-mRNAs when expressed in
FT                   deleted mpn1 yeast cells; when associated with A-208. Slows
FT                   growth in the cold when expressed in deleted mpn1 yeast
FT                   cells; when associated with A-208. Abolishes
FT                   exoribonuclease activity; when associated with A-208.
FT                   Decreases U6 and U6atac motility."
FT                   /evidence="ECO:0000269|PubMed:23022480,
FT                   ECO:0000269|PubMed:23190533, ECO:0000269|PubMed:26213367"
FT   MUTAGEN         120
FT                   /note="H->N: Significantly decreases exonuclease activity."
FT                   /evidence="ECO:0000269|PubMed:30215753"
FT   MUTAGEN         122
FT                   /note="S->C: Significantly decreases exonuclease activity."
FT                   /evidence="ECO:0000269|PubMed:30215753"
FT   MUTAGEN         202
FT                   /note="Y->A: Significantly decreases exonuclease activity."
FT                   /evidence="ECO:0000269|PubMed:30215753"
FT   MUTAGEN         208
FT                   /note="H->A: Abolishes exoribonuclease activity. Does not
FT                   rescue the molecular phenotype caused by USB1 depletion.
FT                   Does not restore U6 snRNA processing when expressed in
FT                   deleted mpn1 yeast cells; when associated with A-120.
FT                   Increases the accumulation of unspliced pre-mRNAs when
FT                   expressed in deleted mpn1 yeast cells; when associated with
FT                   A-120. Slows growth in the cold when expressed in deleted
FT                   mpn1 yeast cells; when associated with A-120. Abolishes
FT                   exoribonuclease activity; when associated with A-120.
FT                   Decreases U6 and U6atac motility."
FT                   /evidence="ECO:0000269|PubMed:22899009,
FT                   ECO:0000269|PubMed:23022480, ECO:0000269|PubMed:23190533,
FT                   ECO:0000269|PubMed:26213367"
FT   MUTAGEN         208
FT                   /note="H->N: Loss of exonuclease activity."
FT                   /evidence="ECO:0000269|PubMed:30215753"
FT   MUTAGEN         208
FT                   /note="H->Q: Loss of exonuclease activity."
FT                   /evidence="ECO:0000269|PubMed:30215753"
FT   MUTAGEN         210
FT                   /note="S->C: Significantly decreases exonuclease activity."
FT                   /evidence="ECO:0000269|PubMed:30215753"
FT   CONFLICT        89
FT                   /note="Y -> C (in Ref. 3; AAH10099)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        209
FT                   /note="L -> P (in Ref. 1; BAB14469)"
FT                   /evidence="ECO:0000305"
FT   STRAND          80..89
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   HELIX           93..107
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   STRAND          117..122
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   STRAND          127..130
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   HELIX           131..133
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   HELIX           134..145
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   STRAND          155..162
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   STRAND          166..175
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   HELIX           179..195
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   STRAND          208..216
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   HELIX           219..222
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   HELIX           225..235
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   HELIX           241..244
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   STRAND          245..247
FT                   /evidence="ECO:0007829|PDB:6D30"
FT   STRAND          250..255
FT                   /evidence="ECO:0007829|PDB:4H7W"
FT   STRAND          258..263
FT                   /evidence="ECO:0007829|PDB:4H7W"
SQ   SEQUENCE   265 AA;  30268 MW;  75D8BF51DF8D353D CRC64;
     MSAAPLVGYS SSGSEDESED GMRTRPGDGS HRRGQSPLPR QRFPVPDSVL NMFPGTEEGP
     EDDSTKHGGR VRTFPHERGN WATHVYVPYE AKEEFLDLLD VLLPHAQTYV PRLVRMKVFH
     LSLSQSVVLR HHWILPFVQA LKARMTSFHR FFFTANQVKI YTNQEKTRTF IGLEVTSGHA
     QFLDLVSEVD RVMEEFNLTT FYQDPSFHLS LAWCVGDARL QLEGQCLQEL QAIVDGFEDA
     EVLLRVHTEQ VRCKSGNKFF SMPLK
//
